Based on these genetic and preclinical data, a phase I/II study combining tazemetostat, a reversible EZH2 inhibitor, with dabrafenib and trametinib (BRAF/MEK inhibition) in patients with BRAF V600E/K mutated melanoma who have previously progressed on prior BRAF/MEK inhibitor therapy is currently active (NCT04557956). This evidence concerns the gene BRAF and melanoma.